Used as a chiral building block in the synthesis of pharmaceutical intermediates, particularly in the development of protease inhibitors and other bioactive molecules. Its structure incorporates both a fluorenylmethyloxycarbonyl (Fmoc) protecting group and a trifluoromethylphenyl moiety, making it valuable in solid-phase peptide synthesis and asymmetric synthesis. The compound is especially useful in creating enantiomerically pure compounds for drug discovery due to its stereochemical integrity and functional group compatibility. It also serves as a key intermediate in the preparation of enzyme inhibitors where the trifluoromethyl group enhances metabolic stability and binding affinity.